ECHA 的信函指出，该注册物质（或其中的杂质）可能属于内分泌干扰物。由于该终点并非标准终点之一，该如何在档案中处理？

ECHA 的信函指出，该注册物质（或其中的杂质）可能属于内分泌干扰物。由于该终点并非标准终点之一，该如何在档案中处理？

ECHA’s letter indicates that the registered substance (or an impurity in it) may be an endocrine disruptor. How should this endpoint be addressed in the dossier, as it is not one of the standard endpoints?

内分泌干扰物可能在毒理学和生态毒理学标准（REACH 附件）测试中表现出来。如上所述，以及在我们的定义文件中更详细地说明，常见的筛选方法正在寻找此类证据。因此，如果根据档案或外部数据对内分泌干扰物（ED）特性存在担忧，注册人可以根据需要进行或提议进行进一步的专业体外或体内 ED 测试。如果有此类测试结果，即使它们不构成标准信息要求，也应将其包含在注册档案中。经合组织（OECD）的《内分泌干扰物测试和评估概念框架》列出了经合组织现有的、正在开发中的或拟议的测试指南和标准化测试方法，这些方法可用于评估物质的内分泌干扰物，并可为内分泌干扰物评估测试提供指导。

Endocrine disruption may manifest itself in toxicological and ecotoxicological standard (in REACH Annexes) tests. As explained above, and in more detail in our definition document, common screening is looking for such evidence. ­Therefore, if there is a concern for ED properties based on the dossier, or external data, registrants might perform or propose further specialised in vitro or in vivo ED tests as necessary. In case such test results are available they should be included in the registration dossier, even if they do not constitute standard information requirements. The OECD Conceptual Framework for Testing and Assessment of Endocrine Disrupters lists the OECD Test Guidelines and standardised test methods available, under development or proposed that can be used to evaluate substances for endocrine disruption and could provide a guide to the tests for endocrine disrupters’ assessment.